These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36648736)

  • 21. Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions.
    Raciti L; Raciti G; Militi D; Casella C; Calabrò RS
    J Integr Neurosci; 2022 Aug; 21(5):141. PubMed ID: 36137961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum CGRP in migraine patients using erenumab as preventive treatment.
    de Vries Lentsch S; Garrelds IM; Danser AHJ; Terwindt GM; MaassenVanDenBrink A
    J Headache Pain; 2022 Sep; 23(1):120. PubMed ID: 36089587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
    Robblee J; Hakim SM; Reynolds JM; Monteith TS; Zhang N; Barad M
    Headache; 2024 May; 64(5):547-572. PubMed ID: 38634515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
    Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
    Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
    J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F; Brunelli N; Messina R; Costa CM; Colombo B; Torelli P; Quintana S; Cevoli S; Favoni V; d'Onofrio F; Egeo G; Rao R; Filippi M; Barbanti P; Altamura C
    J Headache Pain; 2021 Dec; 22(1):154. PubMed ID: 34922444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
    Caronna E; Gallardo VJ; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
    J Headache Pain; 2021 Oct; 22(1):120. PubMed ID: 34620085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.
    Nsaka M; Scheffler A; Wurthmann S; Schenk H; Kleinschnitz C; Glas M; Holle D
    Brain Behav; 2022 Jul; 12(7):e2662. PubMed ID: 35687795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience.
    Raffaelli B; Fitzek M; Overeem LH; Storch E; Terhart M; Reuter U
    J Headache Pain; 2023 Feb; 24(1):16. PubMed ID: 36843007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
    Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
    BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    Eur J Neurol; 2022 May; 29(5):1505-1513. PubMed ID: 35098620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine.
    Siersbæk N; Kilsdal L; Jervelund C; Antic S; Bendtsen L
    BMC Neurol; 2023 Jul; 23(1):254. PubMed ID: 37400756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-regression to explain the placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention.
    Regnier SA; Lee XY
    J Med Econ; 2023; 26(1):1072-1080. PubMed ID: 37594778
    [No Abstract]   [Full Text] [Related]  

  • 35. [Anti-calcitonin generelated peptide (CGRP) therapies for migraine].
    Moisset X; Demarquay G
    Rev Prat; 2023 Feb; 73(2):123-126. PubMed ID: 36916250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
    Nagaraj K; Vandenbussche N; Goadsby PJ
    Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Mullin K; Kudrow D; Croop R; Lovegren M; Conway CM; Coric V; Lipton RB
    Neurology; 2020 May; 94(20):e2121-e2125. PubMed ID: 31932515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
    Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
    Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis.
    Gaul C; Seidel K; Heuck A; Silaidos C; Mrosowsky T; Eberhardt A; Fritz B; Jacob C
    J Med Econ; 2023; 26(1):667-678. PubMed ID: 37126606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis.
    Alasad YW; Asha MZ
    Clin Neurol Neurosurg; 2020 Aug; 195():105900. PubMed ID: 32460120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.